Low Molecular Weight Heparin Market Foreseen Projected to Exceed US$ 5 Billion by 2026 | CAGR: 6.7%: Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/1491

The global low molecular weight heparin market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), By Packaging (Multi-vials and Prefilled Syringes), By Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism and Atrial Fibrillation), By End-Use (Hospitals (Private and Public), Clinics, and Home) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued US$ 3,050.4 million in 2018, and is expected to exhibit a CAGR of 6.7% over the projected period (2018-2026).

Growing inclination of research institutes towards the use of LMWH in a range of novel treatments has augmented the demand of LMWH. The American University of Beirut Medical Centre sponsored the study of a drug, bemiparin sodium (a form of LMWH), which is in phase 4 and helps to improve pregnancy outcomes in patients with recurrent implantation failure undergoing IVF/ ICSI treatment. Furthermore, the major market players have been collaborating with several hospitals to strengthen their product portfolio.

View Press Release For More Information @ https://bit.ly/2YiOx4h

Bayer joined forces with Assistance Publique – Hopitaux de Paris to examine the combination of rivaroxaban and low molecular weight heparin for neoplasm and venous thromboembolism. Both these pipeline drugs are expected to complete their final stages of study over the projected timeline.

As per the latest reports, increasing organic and inorganic growth strategies adopted by the leading manufacturers in the global market would potentially encourage the adoption of LMWH in the following years. For instance, in January 2012, Watson Pharmaceuticals and Amphastar Pharmaceuticals launched Amphastar’s enoxaparin sodium injection. Amphastar and Watson have a distribution agreement under which Amphastar supplies enoxaparin to Watson, which then markets, sells, and distributes the product to retail pharmacies in the U.S.

In July 2018, Pfizer Inc. announced plans to invest US$ 465 million to establish a technically advanced sterile injectable pharmaceutical production facility at Michigan, U.S. Furthermroe, in April 2018, Laboratorios Farmaceúticos Rovi SA signed a license expanding agreement with Hikma Pharmaceuticals PLC for ROVI’s enoxaparin biosimilar because of Hikma’s strong presence in the Middle East and North Africa (MENA) region.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1491 

Key Trends of the Global Low Molecular Weight Heparin Market:

• Among drugs, the enoxaparin segment held a major market share in the global market in 2017. Enoxaparin (Lovenox) is an EU-approved low molecular weight heparin (LMWH) indicated for medical patients with severely restricted mobility during acute illness, prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, inpatient treatment of acute DVT with or without pulmonary embolism, knee replacement surgery, outpatient treatment of acute DVT without pulmonary embolism, prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction (MI).
• The prefilled syringes packaging segment led the global market in 2017, as prefilled syringes are considered the most preferred and effective packaging solution. Moreover, prefilled syringes have gained major traction as delivery systems for injectable drugs, especially in the treatment of chronic conditions that require repeated administration of the medication.
• The Deep Vein Thrombosis (DVT) application segment emerged as a dominant segment in 2017. The home therapy of DVT with LMWH, compared with inpatient therapy with unfractionated heparin, produces comparably better clinical outcomes and patient satisfaction, with cost savings.
• The hospital’s end-user segment dominated the global market in 2017. Low-molecular Weight Heparin (LMWH) is increasingly being used in emergency department and during surgery procedures, owing to the expanding medical infrastructure and increasing surgical procedures.
• The well-known players trading in the global low molecular weight heparin market include Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.

Have a Look at Related Research Insights:

Cancer Biologics Market, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, and Others), By Distribution Channel (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Anti-Cathepsin B Market, by Product Type (Primary Antibodies, Proteins and Peptides, and Lysates), by Application (Cancer, Traumatic Brain Injury, Ebola Infection, Fertility Treatment, and Others), By Technique (Immunohistochemistry, Immunofluorescence, Western Blotting, ELISA, Flow Cytometry, and Others), By End User (Pharmaceutical Companies, and Academic and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Bone Regeneration Material Market, by Product Type (Xenogene, Partially Synthetic Materials, Synthetic Materials, Others), By Application (Orthopaedic Surgery, Bone Trauma, Dental Surgery, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.